FibroBiologics Relocates Offices, Updates Contact Info

Ticker: FBLG · Form: 8-K · Filed: Jun 27, 2024 · CIK: 1958777

Fibrobiologics, INC. 8-K Filing Summary
FieldDetail
CompanyFibrobiologics, INC. (FBLG)
Form Type8-K
Filed DateJun 27, 2024
Risk Levellow
Pages2
Reading Time3 min
Key Dollar Amounts$0.00001
Sentimentneutral

Sentiment: neutral

Topics: administrative, office-move

TL;DR

FibroBiologics moved offices effective 6/25, new address is 455 E. Medical Center Blvd., Suite 300, Houston, TX 77598. Phone updated too.

AI Summary

FibroBiologics, Inc. filed an 8-K on June 27, 2024, reporting a change in its principal executive offices to 455 E. Medical Center Blvd., Suite 300, Houston, Texas 77598, effective June 25, 2024. The company also updated its telephone number to (281) 671-5150. This filing does not involve any financial statements or exhibits.

Why It Matters

A change in principal executive offices can indicate operational shifts or growth for a company. Investors should note the new address and contact details for future correspondence.

Risk Assessment

Risk Level: low — This filing is administrative, detailing a change of address and phone number, with no immediate financial or operational risks disclosed.

Key Players & Entities

FAQ

What is the new address for FibroBiologics, Inc.'s principal executive offices?

The new address for FibroBiologics, Inc.'s principal executive offices is 455 E. Medical Center Blvd., Suite 300, Houston, Texas 77598.

When was the change in principal executive offices effective?

The change in principal executive offices was effective as of June 25, 2024.

What is the updated telephone number for FibroBiologics, Inc.?

The updated telephone number for FibroBiologics, Inc. is (281) 671-5150.

What is the state of incorporation for FibroBiologics, Inc.?

FibroBiologics, Inc. is incorporated in Delaware.

What is the SIC code for FibroBiologics, Inc.?

The Standard Industrial Classification (SIC) code for FibroBiologics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.

Filing Stats: 732 words · 3 min read · ~2 pages · Grade level 14.2 · Accepted 2024-06-27 07:22:46

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Date: June 27, 2024 FibroBiologics, Inc. By: /s/ Pete O'Heeron Name: Pete O'Heeron Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing